INBX
INSIDER BUYINSIDER SELLInhibrx Biosciences, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
PositiveINBX achieved two major regulatory/clinical milestones since June 30, 2026: FDA BLA acceptance for ozekibart in chondrosarcoma and strong Phase 2 HNSCC data for INBRX-106 (48.3% cORR, nearly double comparators), providing clear late-stage validation. The company secured substantial debt financing ($325M additional from Oxford Finance) extending runway, though this increased net losses ($36.7M in Q2 2026, up YoY) and triggered negative stock reaction; CEO insider buying in late September signals management confidence despite the debt-heavy capital structure.
Red flags
- •Net losses accelerating: Q2 2026 loss of $36.7M vs. $28.7M in Q2 2025; EPS miss consensus slightly
- •No product revenue in Q2 2026 (vs. $1.3M license revenue in Q2 2025); clinical-stage burn remains high
- •Large debt facility ($500M total capacity) introduces financial risk and debt-service obligations; stock fell on financing announcement, signaling dilution/leverage concerns
- •Cash runway extended but still finite (~$219.5M as of early August plus additional draws); path to profitability unclear absent near-term approvals
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| Lappe Mark | Chief Executive Officer | BUY | 2K | $98.88 | $0.15M | 2026-09-28 | ↗ |
| Lappe Mark | Chief Executive Officer | BUY | 3K | $101.70 | $0.31M | 2026-09-28 | ↗ |
| Lappe Mark | Chief Executive Officer | BUY | 2K | $99.60 | $0.22M | 2026-09-25 | ↗ |
| Lappe Mark | Chief Executive Officer | BUY | 3K | $98.87 | $0.33M | 2026-09-25 | ↗ |
| Kayyem Jon Faiz | — | BUY | 5K | $100.00 | $0.50M | 2026-09-23 | ↗ |
| Kayyem Jon Faiz | — | BUY | 5K | $100.00 | $0.50M | 2026-09-16 | ↗ |
| MANHARD KIMBERLY | — | SELL | 500 | $105.05 | $0.05M | 2026-09-15 | ↗ |
| MANHARD KIMBERLY | — | SELL | 500 | $110.26 | $0.06M | 2026-09-14 | ↗ |
| MANHARD KIMBERLY | — | SELL | 500 | $111.78 | $0.06M | 2026-09-11 | ↗ |
| MANHARD KIMBERLY | — | SELL | 500 | $115.80 | $0.06M | 2026-09-09 | ↗ |
| Lappe Mark | Chief Executive Officer | BUY | 10K | $112.28 | $1.09M | 2026-09-08 | ↗ |
| MANHARD KIMBERLY | — | SELL | 500 | $115.14 | $0.06M | 2026-09-08 | ↗ |
| Kayyem Jon Faiz | — | BUY | 5K | $113.52 | $0.57M | 2026-09-08 | ↗ |
| FORSYTH DOUGLAS | — | BUY | 3K | $114.65 | $0.29M | 2026-09-08 | ↗ |
| Lappe Mark | Chief Executive Officer | BUY | 6K | $99.29 | $0.59M | 2026-09-08 | ↗ |
| Lappe Mark | Chief Executive Officer | BUY | 7K | $100.64 | $0.66M | 2026-09-08 | ↗ |
| Lappe Mark | Chief Executive Officer | BUY | 1K | $107.12 | $0.12M | 2026-09-08 | ↗ |
| Lappe Mark | Chief Executive Officer | BUY | 500 | $108.23 | $0.05M | 2026-09-08 | ↗ |
| Lappe Mark | Chief Executive Officer | BUY | 1K | $111.88 | $0.14M | 2026-09-08 | ↗ |
Fund 13D/13G Filings (3)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Viking Global | SC 13G/A | −78K | 9.3% | +7.0% vs SPY +7.0% abs | 2026-08-14 | ↗ |
| Viking Global | SC 13G/A | — | 10.0% | -16.2% vs SPY -10.7% abs | 2026-05-15 | ↗ |
| Viking Global | SC 13G/A | — | 10.0% | — | 2026-02-17 | ↗ |
Tracked Funds Holding (2)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Viking Global | Andreas Halvorsen | 1.1M | $106M |
| Point72 | Steve Cohen | 26K | $2M |
Quarter-end 13F positions for the tracked funds holding this stock.